A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

Active, not recruiting · Phase 3 · NCT02629159

Conditions: Rheumatoid Arthritis

Research payments reported, 2025: $312,434
U.S. investigators named: 31
Sites paid: 28
Planned or actual enrollment: 1,629

About the trial

Sponsor: AbbVie
Tested: Placebo for Adalimumab (drug), Adalimumab (drug), Placebo for Upadacitinib (drug), Upadacitinib (drug)
Dates: Started 2015-12-01; completion 2027-09-30
Results posted: Yes

The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.

From ClinicalTrials.gov, last updated 2025-08-05. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $312,434 in research payments for this study in 2025 (205 payments).

Products named: Rinvoq

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it